These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15952870)

  • 1. Preclinical drug safety analysis by chemogenomic profiling in the liver.
    Fielden MR; Pearson C; Brennan R; Kolaja KL
    Am J Pharmacogenomics; 2005; 5(3):161-71. PubMed ID: 15952870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system drug development: an integrative biomarker approach toward individualized medicine.
    Gomez-Mancilla B; Marrer E; Kehren J; Kinnunen A; Imbert G; Hillebrand R; Bergström M; Schmidt ME
    NeuroRx; 2005 Oct; 2(4):683-95. PubMed ID: 16489375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK.
    Cavero I
    Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chipping away at the mystery of drug responses.
    Rockett JC
    Pharmacogenomics J; 2001; 1(3):161-3. PubMed ID: 11908748
    [No Abstract]   [Full Text] [Related]  

  • 8. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
    Kramer JA; Kolaja KL
    Expert Opin Drug Saf; 2002 Sep; 1(3):275-86. PubMed ID: 12904143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents.
    Luo L; Schomaker S; Houle C; Aubrecht J; Colangelo JL
    Toxicol Sci; 2014 Jan; 137(1):12-25. PubMed ID: 24085190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
    Atterwill CK; Wing MG
    Toxicol Lett; 2002 Feb; 127(1-3):143-51. PubMed ID: 12052652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time- and dose-based gene expression profiles produced by a bile-duct-damaging chemical, 4,4'-methylene dianiline, in mouse liver in an acute phase.
    Kwon SB; Park JS; Yi JY; Hwang JW; Kim M; Lee MO; Lee BH; Kim HL; Kim JH; Chung H; Kong G; Kang KS; Yoon BI
    Toxicol Pathol; 2008 Jul; 36(5):660-73. PubMed ID: 18648102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising toxicological biomarkers for the diagnosis of liver injury types: Bile acid metabolic profiles and oxidative stress marker as screening tools in drug development.
    Masubuchi N; Nishiya T; Imaoka M; Mizumaki K; Okazaki O
    Chem Biol Interact; 2016 Aug; 255():74-82. PubMed ID: 26365562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the chemogenomic knowledge space with annotated chemical libraries.
    Savchuk NP; Balakin KV; Tkachenko SE
    Curr Opin Chem Biol; 2004 Aug; 8(4):412-7. PubMed ID: 15288252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro.
    Gunther EC; Stone DJ; Gerwien RW; Bento P; Heyes MP
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9608-13. PubMed ID: 12869696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and its potential impact on drug and formulation development.
    Regnstrom K; Burgess DJ
    Crit Rev Ther Drug Carrier Syst; 2005; 22(5):465-92. PubMed ID: 16313234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DNA microarrays--perspective of application for drug effectivity and safety evaluation].
    Roman I
    Postepy Biochem; 2008; 54(1):107-15. PubMed ID: 18610588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the Safety Assessment of Chemicals and Drug Candidates by the Integration of Bioinformatics and Chemoinformatics Data.
    Steger-Hartmann T; Pognan F
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():29-36. PubMed ID: 29316298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.